Beneficial effects of poplar buds on hyperglycemia, dyslipidemia, oxidative stress, and inflammation in streptozotocin-induced type-2 diabetes

Journal of Immunology Research

Volumn 2018, Issue , 2018, Pages

  Peng, Shiqin ^a   Wei, Ping ^a   Lu, Qun ^a,b,c   Liu, Rui ^a,b,c   Ding, Yue ^a   Zhang, Jiuliang ^a,b,c  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b Wuhan Research Center on Quality Control Engineering of Bee Products   (China)

^c KEY LABORATORY OF ENVIRONMENT CORRELATIVE DIETOLOGY HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CRUDE EXTRACT OF POPLAR BUD; CYCLOOXYGENASE 2; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; PROPOLIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BUD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER HOMOGENATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; POPULUS; PROTEIN BLOOD LEVEL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL LEVEL; ANIMAL; DIABETIC COMPLICATION; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HUMAN; IMMUNOLOGY; INBRED MOUSE STRAIN; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ANIMALS; CYCLOOXYGENASE 2; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED STRAINS; OXIDATIVE STRESS; PLANT EXTRACTS; POPULUS; PROPOLIS;

EID: 85054889816     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2018/7245956     Document Type: Article

References (42)

1. N. Samadi, H. Mozaffari-Khosravi, M. Rahmanian, and M. Askarishahi, “Effects of bee propolis supplementation on glycemic control, lipid profile and insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial,” Journal of Integrative Medicine, vol. 15, no. 2, pp. 124–134, 2017.
2. A. H. Al-Assaf, “Antihyperglycemic and antioxidant effect of ginger extract on streptozotocin-diabetic rats,” Pakistan Journal of Nutrition, vol. 11, no. 12, pp. 1107–1112, 2012.
3. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013.
4. International Diabetes Federation, IDF Diabetes Atlas, 8th edition, http://www.diabetesatlas.org/.
5. G. A. Burdock, “Review of the biological properties and toxicity of bee propolis (propolis),” Food and Chemical Toxicology, vol. 36, no. 4, pp. 347–363, 1998.
6. P. G. Pietta, C. Gardana, and A. M. Pietta, “Analytical methods for quality control of propolis,” Fitoterapia, vol. 73, pp. S7–S20, 2002.
7. S. Dudonné, P. Poupard, P. Coutière et al., “Phenolic composition and antioxidant properties of poplar bud (Populus nigra) extract: individual antioxidant contribution of phenolics and transcriptional effect on skin aging,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4527–4536, 2011.
8. J. Havlik, V. Rada, and V. Plachy, “Xanthine oxidase-inhibitory and hypouricemic action of black poplar bud extract,” Planta Medica, vol. 77, no. 12, 2011.
9. K. Wang, J. Zhang, S. Ping et al., “Anti-inflammatory effects of ethanol extracts of Chinese propolis and buds from poplar (Populus × canadensis),” Journal of Ethnopharmacology, vol. 155, no. 1, pp. 300–311, 2014.
10. S. De Marco, M. Piccioni, R. Pagiotti, and D. Pietrella, “Anti-biofilm and antioxidant activity of propolis and bud poplar resins versus Pseudomonas aeruginosa,” Evidence-based Complementary and Alternative Medicine, vol. 2017, Article ID 5163575, 11 pages, 2017.
11. P. V. A. Babu, D. Liu, and E. R. Gilbert, “Recent advances in understanding the anti-diabetic actions of dietary flavonoids,” The Journal of Nutritional Biochemistry, vol. 24, no. 11, pp. 1777–1789, 2013.
12. W. Ping, D. Yue, L. Qun, T. Jun, Z. Jiuliang, and L. Rui, “Flavonoids in propolis and poplar resin and their inhibition of α-glucosidase activity,” Journal of Huazhong Agricultural University, vol. 37, no. 3, 2018.
13. J. Rozman, B. Rathkolb, S. Neschen et al., “Glucose tolerance tests for systematic screening of glucose homeostasis in mice,” in Current Protocols in Mouse Biology, John Wiley & Sons, Inc., 2011.
14. N. F. Abdul Sani, L. K. Belani, C. Pui Sin et al., “Effect of the combination of gelam honey and ginger on oxidative stress and metabolic profile in streptozotocin-induced diabetic Sprague-Dawley rats,” BioMed Research International, vol. 2014, Article ID 160695, 9 pages, 2014.
15. M. Kherroubi, M. Buysschaert, and F. Pollak, “Dyslipidemia and type 2 diabetes mellitus,” Louvain Médical, vol. 126, no. 5, pp. 121–127, 2007.
16. M. X. Fu, J. R. Requena, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe, “The advanced glycation end product, Nep-silon-(carboxymethyl)lysine, is a product of both lipid peroxi-dation and glycoxidation reactions,” The Journal of Biological Chemistry, vol. 271, no. 17, pp. 9982–9986, 1996.
17. A. C. Maritim, R. A. Sanders, and J. B. Watkins, “Diabetes, oxidative stress, and antioxidants: a review,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 24–38, 2003.
18. P. J. Thornalley, A. Langborg, and H. S. Minhas, “Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose,” The Biochemical Journal, vol. 344, no. 1, pp. 109–116, 1999.
19. N. Oršolić, D. Sirovina, M. Z. Končić, G. Lacković, and G. Gregorović, “Effect of Croatian propolis on diabetic nephropathy and liver toxicity in mice,” BMC Complementary and Alternative Medicine, vol. 12, p. 117, 2012.
20. W. Zhu, Y.-H. Li, M.-L. Chen, and F.-L. Hu, “Protective effects of Chinese and Brazilian propolis treatment against hepatore-nal lesion in diabetic rats,” Human & Experimental Toxicology, vol. 30, no. 9, pp. 1246–1255, 2010.
21. E.-S. M. El-Sayed, O. M. Abo-Salem, H. A. Aly, and A. M. Mansour, “Potential antidiabetic and hypolipidemic effects of propolis extract in streptozotocin-induced diabetic rats,” Pakistan Journal of Pharmaceutical Sciences, vol. 22, no. 2, pp. 168–174, 2009.
22. J. Thulesen, C. Orskov, J. J. Holst, and S. S. Poulsen, “Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats,” Endocrinology, vol. 138, no. 1, pp. 62–68, 1997.
23. J. K. Cruickshank, “Survival as a function of HbA1c in people with type 2 diabetes,” The Lancet, vol. 375, no. 9724, p. 1434, 2010.
24. M. I. Oladayo, “Nigerian propolis improves blood glucose, glycated hemoglobin A1c, very low-density lipoprotein, and high-density lipoprotein levels in rat models of diabetes,” Journal of Intercultural Ethnopharmacology, vol. 5, no. 3, pp. 233–238, 2016.
25. A. D. Mooradian, “Dyslipidemia in type 2 diabetes mellitus,” Nature Clinical Practice. Endocrinology & Metabolism, vol. 5, no. 3, pp. 150–159, 2009.
26. M. R. Taskinen and J. Boren, “New insights into the patho-physiology of dyslipidemia in type 2 diabetes,” Atherosclerosis, vol. 239, no. 2, pp. 483–495, 2015.
27. W. Aoi, S. Hosogi, N. Niisato et al., “Improvement of insulin resistance, blood pressure and interstitial pH in early developmental stage of insulin resistance in OLETF rats by intake of propolis extracts,” Biochemical and Biophysical Research Communications, vol. 432, no. 4, pp. 650–653, 2013.
28. B. C. Martin, J. H. Warram, A. S. Krolewski et al., “Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study,” The Lancet, vol. 340, no. 8825, pp. 925–929, 1992.
29. L. A. Elissa, N. M. Elsherbiny, and A. O. Magmomah, “Propolis restored adiponectin level in type 2 diabetes through PPARγ activation,” Egyptian Journal of Basic and Applied Sciences, vol. 2, no. 4, pp. 318–326, 2015.
30. L. Zhao, L. Pu, J. Wei et al., “Brazilian green propolis improves antioxidant function in patients with type 2 diabetes mellitus,” International Journal of Environmental Research and Public Health, vol. 13, no. 5, 2016.
31. C. P. Domingueti, L. M. S.'. A. Dusse, M. d. G. Carvalho, L. P. de Sousa, K. B. Gomes, and A. P. Fernandes, “Diabetes mellitus: the linkage between oxidative stress, inflammation, hyper-coagulability and vascular complications,” Journal of Diabetes and its Complications, vol. 30, no. 4, pp. 738–745, 2016.
32. K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005.
33. O. Aouacheri, S. Saka, M. Krim, A. Messaadia, and I. Maidi, “The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus,” Canadian Journal of Diabetes, vol. 39, no. 1, pp. 44–49, 2015.
34. M. Ståhlman, B. Fagerberg, M. Adiels et al., “Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1831, no. 11, pp. 1609–1617, 2013.
35. S. Margetic, “Inflammation and haemostasis,” Biochemia Medica, vol. 22, no. 1, pp. 49–62, 2012.
36. J. Scheller, A. Chalaris, D. Schmidt-Arras, and S. Rose-John, “The pro- and anti-inflammatory properties of the cytokine interleukin-6,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1813, no. 5, pp. 878–888, 2011.
37. H. Tilg, E. Trehu, M. B. Atkins, C. A. Dinarello, and J. W. Mier, “Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55,” Blood, vol. 83, no. 1, pp. 113–118, 1994.
38. A. Remppis, F. Bea, H. J. Greten et al., “Rhizoma coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFκB-dependent pathway,” Mediators of Inflammation, vol. 2010, Article ID 194896, 8 pages, 2010.
39. A. Dihingia, D. Ozah, P. K. Baruah, J. Kalita, and P. Manna, “Prophylactic role of vitamin K supplementation on vascular inflammation in type 2 diabetes by regulating the NF-κB/ Nrf2 pathway via activating Gla proteins,” Food & Function, vol. 9, no. 1, pp. 450–462, 2018.
40. L. F. T. Martin, E. M. Rocha, S. B. Garcia, and J. S. Paula, “Topical Brazilian propolis improves corneal wound healing and inflammation in rats following alkali burns,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, p. 337, 2013.
41. H. A. El Rabey, M. N. Al-Seeni, and A. S. Bakhashwain, “The antidiabetic activity of Nigella sativa and propolis on streptozotocin-induced diabetes and diabetic nephropathy in male rats,” Evidence-based Complementary and Alternative Medicine, vol. 2017, Article ID 5439645, 14 pages, 2017.
42. J. Huang, X. Wang, G. Tao et al., “Feruloylated oligosaccha-rides from maize bran alleviate the symptoms of diabetes in streptozotocin-induced type 2 diabetic rats,” Food & Function, vol. 9, no. 3, pp. 1779–1789, 2018.